Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future
protection of individuals and populations against SARS-CoV-2. Moreover, passively …

Background We conducted a trial of prophylactic platelet transfusions to evaluate the effect of
platelet dose on bleeding in patients with hypoproliferative thrombocytopenia. Methods We …

As infectious complications from blood transfusion have decreased because of improved
donor questionnaires and sophisticated infectious disease blood screening, noninfectious …

Bacterial contamination of transfusion products, especially platelets, is a longstanding problem
that has been partially controlled through modern phlebotomy practices, refrigeration of …

BACKGROUND: Antibodies to human leukocyte antigens (HLA) in donated blood have been
implicated as a cause of transfusion‐related acute lung injury (TRALI). A potential measure …

The aging of the US population and the evidence that only about 5% of individuals in the
United States donate blood each year raise concerns about the assurance of an adequate, safe …

BACKGROUND: Recent data from military and civilian centers suggest that mortality is
decreased in massive transfusion patients by increasing the transfusion ratio of plasma and …

The development of neutralizing antibodies (NAbs) against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) following infection or vaccination is likely to be critical for …

Dear Editor, The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) highlights the need to develop effective …

The clinical outcomes of sickle cell disease (SCD) have vastly improved over the years in
great part as a result of advanced medical technologies, improved patient education, and …